semaj83/ctmatch_classification huggingface dataset:
Patient description: A 46-year-old woman presents with a 9 month history of weight loss (20 lb), sweating, insomnia and diarrhea. She reports to have been eating more than normal and that her heart sometimes races for no reason. On physical examination her hands are warm and sweaty, her pulse is irregular at 110bpm and there is hyperreflexia and mild exophthalmia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Recurrent Thyroid Cancer Stage IVA Follicular Thyroid Cancer Stage IVA Papillary Thyroid Cancer Stage IVB Follicular Thyroid Cancer Stage IVB Papillary Thyroid Cancer Stage IVC Follicular Thyroid Cancer Stage IVC Papillary Thyroid Cancer Histologically confirmed papillary thyroid or follicular thyroid carcinoma Differentiated disease Metastatic disease documented by ultrasound, computed tomography (CT) scan (without iodinated contrast), or MRI All metastatic disease foci =< 10 mm in all dimensions Must have been treated with total or near-total thyroidectomy AND at least 1 course of iodine I 131 (131I)(>=29.9 mCi) OR demonstrated negative uptake on a postoperative low-dose131I scan Must have undergone whole body 131I scan 1-3 days after administration of =< 5.5 mCi of 131I demonstrating no visible iodine uptake within the lesions unless demonstrated negative uptake on a postoperative low-dose131I scan within the past 12 weeks Must have 24-hour urine iodine excretion =< 500 mcg within 1 week of 131I scan Must be receiving thyroid hormone therapy AND have thyroid-stimulating hormone level =< 0.5 mU/L No known brain metastases Performance status
Patient description: A 46-year-old woman presents with a 9 month history of weight loss (20 lb), sweating, insomnia and diarrhea. She reports to have been eating more than normal and that her heart sometimes races for no reason. On physical examination her hands are warm and sweaty, her pulse is irregular at 110bpm and there is hyperreflexia and mild exophthalmia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Thyroid Neoplasms Total or near total thyroidectomy performed for papillary or follicular thyroid cancer R0-1 resection, no macroscopic cancer left behind at surgery Physically and emotionally able to undergo radioiodine treatment A written informed consent  Pregnancy Physical or psychiatric illness that may deteriorate during the isolation period required by radioiodine therapy
Patient description: A 46-year-old woman presents with a 9 month history of weight loss (20 lb), sweating, insomnia and diarrhea. She reports to have been eating more than normal and that her heart sometimes races for no reason. On physical examination her hands are warm and sweaty, her pulse is irregular at 110bpm and there is hyperreflexia and mild exophthalmia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Benign Nontoxic and Toxic Goiter Graves' Disease Healthy volunteers with an intact thyroid gland Patients with nontoxic/subtoxic nodular goiter confirmed by ultrasonography Patients with toxic nodular goiter Patients with Graves' disease  Treatment with drugs that alter thyroid function or size (the last 3 months prior to inclusion) Prior 131I treatment Alcohol, medicine or drug abuse Pregnancy or lactation No safe contraception Participation in another clinical trial Allergic reaction towards rhTSH Fine needle biopsy without valid diagnostic for benign disease Suspicion of malignancy, increased ionized serum calcium and/or serum calcitonin Incontinence
Patient description: A 46-year-old woman presents with a 9 month history of weight loss (20 lb), sweating, insomnia and diarrhea. She reports to have been eating more than normal and that her heart sometimes races for no reason. On physical examination her hands are warm and sweaty, her pulse is irregular at 110bpm and there is hyperreflexia and mild exophthalmia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Graves´ Disease Thyroid Associated Ophthalmopathy Graves´ disease Adequate anticonception in women  Performance status >2 Previous rituximab treatment Immunosuppressive treatment Serious concomitant disease Active infections Pregnancy / breast feeding
Patient description: A 46-year-old woman presents with a 9 month history of weight loss (20 lb), sweating, insomnia and diarrhea. She reports to have been eating more than normal and that her heart sometimes races for no reason. On physical examination her hands are warm and sweaty, her pulse is irregular at 110bpm and there is hyperreflexia and mild exophthalmia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Toxic Nodular Goitre Graves' Disease Hyperthyroid patients going to be treated with radioiodine either due to recurrent Graves' disease or toxic nodular goiter  Age < 18 yrs Allergy to anti-thyroid drugs Substernal or large (> 100ml) goiter Severe endocrine ophthalmopathy Pregnancy or lactation Suspicion of thyroid malignancy Unsafe contra-conception Physical or mental condition that hinders corporation
Patient description: A 46-year-old woman presents with a 9 month history of weight loss (20 lb), sweating, insomnia and diarrhea. She reports to have been eating more than normal and that her heart sometimes races for no reason. On physical examination her hands are warm and sweaty, her pulse is irregular at 110bpm and there is hyperreflexia and mild exophthalmia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Toxic Nodular Goitre Graves Disease Hyperthyroid patients going to be treated with radioiodine either due to recurrent Graves’ disease or toxic nodular goiter  Age < 18 yrs Allergy to anti-thyroid drugs Substernal or large (> 100ml) goiter Severe endocrine ophthalmopathy Pregnancy or lactation Suspicion of thyroid malignancy Unsafe contraconception Physical or mental condition that hinders corporation
Patient description: A 46-year-old woman presents with a 9 month history of weight loss (20 lb), sweating, insomnia and diarrhea. She reports to have been eating more than normal and that her heart sometimes races for no reason. On physical examination her hands are warm and sweaty, her pulse is irregular at 110bpm and there is hyperreflexia and mild exophthalmia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Obesity healthy males Normal weigh, e.i. BMI between 18,5-25 kg/m2 age 18-40 years  donation of blood 3 monhts prior or during the study gastrointestinal disorders, diabetes, hypertension, hyperlipidemia, chronic infectious disease smoking consumption of more than 21 alcoholic drinks/week elite athletes on mediation diet supplements
Patient description: A 46-year-old woman presents with a 9 month history of weight loss (20 lb), sweating, insomnia and diarrhea. She reports to have been eating more than normal and that her heart sometimes races for no reason. On physical examination her hands are warm and sweaty, her pulse is irregular at 110bpm and there is hyperreflexia and mild exophthalmia.

Clinical trial eligibility criteria: eligible ages (years): 40.0-65.0,  Obesity BMI greater than 30 African American 46 years old  bariatric surgery within the previous 5 years
Patient description: A 46-year-old woman presents with a 9 month history of weight loss (20 lb), sweating, insomnia and diarrhea. She reports to have been eating more than normal and that her heart sometimes races for no reason. On physical examination her hands are warm and sweaty, her pulse is irregular at 110bpm and there is hyperreflexia and mild exophthalmia.

Clinical trial eligibility criteria: eligible ages (years): 21.0-60.0,  Graves Ophthalmopathy Confirmed TED (as defined by Bartley and Gorman19) Eyelid retraction (upper eyelid margin at or above the superior corneoscleral limbus in primary gaze without frontalis muscle contraction) in association with any one of the following Thyroid dysfunction or abnormal regulation (increased serum thyroxine or triiodothyronine level, decreased serum thyroid stimulating hormone level, absence of thyroid radioiodine uptake suppression after administration of triiodothyronine, or the presence of thyroid stimulating immunoglobulins in serum) Exophthalmos (Hertel measurement of at least 20mm) Extraocular muscle involvement (restrictive myopathy or objective evidence of enlarged muscles) Optic nerve dysfunction (abnormal visual acuity, colour vision, pupillary reaction or perimetry not attributable to other causes) Thyroid dysfunction or abnormal regulation in association with any one of the following -Exophthalmos Extraocular muscle involvement Optic nerve dysfunction  Previous treatment for TED Oral steroids (e.g. immunosuppressive dose) for last 3 months, radiotherapy Intravenous pulsed steroid or methrotrexate therapy Medically unfit to receive I/V high-dose pulsed methylprednisolone or methotrexate History of cardiac arrthymias, recent acute myocardial infarction History of seizure History of acute bleeding peptic ulcer History of pulmonary tuberculosis, Hepatitis B carrier, Hepatitis C positivity, HIV Uncontrolled diabetes or hypertension (to be eligible for the trial, random blood glucose must be < 11.1 mmol/L and blood pressure must be 140/90 or lower#. If above these limits, patients can be treated and reviewed at 2 weeks for enrolment when are met provided the patient does not have optic neuropathy)
Patient description: A 46-year-old woman presents with a 9 month history of weight loss (20 lb), sweating, insomnia and diarrhea. She reports to have been eating more than normal and that her heart sometimes races for no reason. On physical examination her hands are warm and sweaty, her pulse is irregular at 110bpm and there is hyperreflexia and mild exophthalmia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Aging Balance Sleep Males and females Aged 18 to 35, or 60 to 85 Lived at Denver altitude or higher for at least one year Stable treated diseases: thyroid dysfunction (including hypothyroidism and hyperthyroidism), hypertension, hypercholesterolemia, urinary incontinence, prostate enlargement, gastroesophageal reflux disease, irritable bowel syndrome  Aged 36 to 59, under 18, or over 85 BMI less than 18.6 or greater than 30 kg/m2, women below 95 pounds regardless of BMI Sleep duration is less than 5 or more than 9 hours Sensitivity to sleeping medications Night work in the preceding 6 months Transmeridian travel (across more than 2 time zones) in the last 1 month Bone mineral density DXA T-score of less than -1.75 Orthostatic intolerance Prior history of falls in past year Prior history of injurious fall in past 5 years
Patient description: A 46-year-old woman presents with a 9 month history of weight loss (20 lb), sweating, insomnia and diarrhea. She reports to have been eating more than normal and that her heart sometimes races for no reason. On physical examination her hands are warm and sweaty, her pulse is irregular at 110bpm and there is hyperreflexia and mild exophthalmia.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Thyroid Neoplasms Thyroid Nodules Graves Disease Goiter Patients underwent thyroidectomy in Srinagarind hospital, Khonkaen University  Patients with cervical lymph nodes metastases requiring neck dissection Patients that tissue pathology shown anaplastic carcinoma Patients with clinical or laboratory indicators of coagulation disorders
Patient description: A 46-year-old woman presents with a 9 month history of weight loss (20 lb), sweating, insomnia and diarrhea. She reports to have been eating more than normal and that her heart sometimes races for no reason. On physical examination her hands are warm and sweaty, her pulse is irregular at 110bpm and there is hyperreflexia and mild exophthalmia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Carcinoma, Islet Cell Carcinoma, Pancreas Well-differentiated advanced/metastatic pancreatic islet cell tumor Tumor has shown progression within the past year  Current treatment with any chemotherapy, chemoembolization therapy, immunotherapy, or investigational anticancer agent other than somatostatin analogues Prior treatment with any tyrosine kinase inhibitors or anti-VEGF[Vascular endothelial growth factor] angiogenic inhibitors Prior treatment with non-VEGF-targeted angiogenic inhibitors is permitted
Patient description: A 46-year-old woman presents with a 9 month history of weight loss (20 lb), sweating, insomnia and diarrhea. She reports to have been eating more than normal and that her heart sometimes races for no reason. On physical examination her hands are warm and sweaty, her pulse is irregular at 110bpm and there is hyperreflexia and mild exophthalmia.

Clinical trial eligibility criteria: eligible ages (years): 14.0-61.0,  Graves Disease Graves disease  Anticoagulant usage Previous thyroid operation Refused to participate in this study
Patient description: A 46-year-old woman presents with a 9 month history of weight loss (20 lb), sweating, insomnia and diarrhea. She reports to have been eating more than normal and that her heart sometimes races for no reason. On physical examination her hands are warm and sweaty, her pulse is irregular at 110bpm and there is hyperreflexia and mild exophthalmia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Subclinical Hypothyroidism Hyperthyroidism Thyroid Dysfunction patients with subclinical hypothyroidism or hyperthyroidism patients with thyroid nodules and normal thyroid function  patients who are taking thyroxine, antithyroid drugs, lithium or amiodarone patients who had thyroid surgery or radioiodine therapy patients with NYHA class 3 or 4 heart failure
Patient description: A 46-year-old woman presents with a 9 month history of weight loss (20 lb), sweating, insomnia and diarrhea. She reports to have been eating more than normal and that her heart sometimes races for no reason. On physical examination her hands are warm and sweaty, her pulse is irregular at 110bpm and there is hyperreflexia and mild exophthalmia.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Thyroid Cancer histologically confirmed differentiated thyroid cancer status after total thyroidectomy status after subsequent high-dose radioiodine treatment regular follow-up by a board-certified dentist a minimum follow-up of 1 year after radioiodine therapy  anaplastic thyroid cancer
Patient description: A 46-year-old woman presents with a 9 month history of weight loss (20 lb), sweating, insomnia and diarrhea. She reports to have been eating more than normal and that her heart sometimes races for no reason. On physical examination her hands are warm and sweaty, her pulse is irregular at 110bpm and there is hyperreflexia and mild exophthalmia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Obesity healthy meals BMI 24-31 kg/m2 age between 18-50 years hemoglobin >8 mmol/L  donation of blood 6 months before and under the study milk allergy, diabetes, hypertension, hyperlipidemia, cronic infectious disease use of dietary supplements 3 months before and under the study smoking elite athletes use of medication
Patient description: A 46-year-old woman presents with a 9 month history of weight loss (20 lb), sweating, insomnia and diarrhea. She reports to have been eating more than normal and that her heart sometimes races for no reason. On physical examination her hands are warm and sweaty, her pulse is irregular at 110bpm and there is hyperreflexia and mild exophthalmia.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hyperthyroidism Cardiovascular Diseases Atrial Fibrillation Patients: Radioiodine treatment for hyperthyroidism given in the Tampere University Hospital between January 1969 and June 2002 Controls: age and gender-matched control subject identified for each patient from the Population Register Centre. The control subject had to be alive at the time when the patient received the first RAI treatment
Patient description: A 46-year-old woman presents with a 9 month history of weight loss (20 lb), sweating, insomnia and diarrhea. She reports to have been eating more than normal and that her heart sometimes races for no reason. On physical examination her hands are warm and sweaty, her pulse is irregular at 110bpm and there is hyperreflexia and mild exophthalmia.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Neoplasms, Gastrointestinal Tract Specific Information regarding warnings, precautions, contraindications, adverse events, and other pertinent information on the investigational product that may impact subject is provided in the Investigator's Brochure (IB) Pilot Part Subjects eligible for enrollment in the Pilot Part of the study must meet all of the following Signed informed consent Male or female; ≥ 20 years (at the time of giving consent) Any histologically or cytologically confirmed gastric carcinoma independent of tumor ErbB2 status Subjects who have received one prior regimen for gastric carcinoma and developed disease progression or recurrence. The regimen must have contained 5-fluoropyrimidine and/or cisplatin Left ventricular ejection fraction (LVEF) within institutional range of normal as measured by echocardiogram (ECHO). Multigated acquisition (MUGA) scans will be accepted in cases where an echocardiogram cannot be performed or is inconclusive (LVEF of ≥50% required if normal range of LVEF is not provided by institution) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 Able to swallow and retain oral medication Women and men with potential to have children must be willing to practice acceptable methods of birth control during the study  Subjects meeting any of the following must not be enrolled in the study Pregnant or lactating female at anytime during the study Planned concurrent anti-cancer therapy (chemotherapy, radiotherapy, immunotherapy, biologic therapy, hormonal therapy) while taking investigational treatment Unresolved or unstable, serious toxicity from prior cancer treatment (any toxicities greater than grade 2) Peripheral neuropathy of Grade 2 or greater Malabsorption syndrome, disease significantly affecting gastrointestinal function. Subjects with ulcerative colitis and Crohn's disease are also excluded History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, are eligible Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety Life threatening infection Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent
Patient description: A 46-year-old woman presents with a 9 month history of weight loss (20 lb), sweating, insomnia and diarrhea. She reports to have been eating more than normal and that her heart sometimes races for no reason. On physical examination her hands are warm and sweaty, her pulse is irregular at 110bpm and there is hyperreflexia and mild exophthalmia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Advanced Cancer Anorexia Weight Loss Insomnia Advanced cancer patients seen in outpatient clinics or inpatient units at MD Anderson Cancer Center, with presence of anorexia for at least one month, and accompanied by weight loss of > 5 % of pre-illness body weight in the last 6 months. Anorexia on the day of enrollment (day 0 +/-3) must be > 4/10 on ESAS Patients > 18 years of age Karnofsky Performance score of > 40 at time of into study Ability to provide informed consent and comply with study procedures Ability and willingness to return to engage in telephone follow-up by research nurse on days 2 (+/ days), 8 (+/ days), 16 ( +/ days), and 22 (+/ days) and return to outpatient clinic for evaluation on days 15 (+/ days), and 29 (+/  Patients who have known dementia or delirium at time of enrollment as determined by a physician Known hypersensitivity to any ingredient of Mirtazapine Inability to maintain oral intake over the course of the study, such as with mechanical obstruction of the alimentary tract or intractable vomiting Ongoing use of tube feeding or parenteral nutrition Current use of corticosteroids (with the exception of scheduled doses during time of chemotherapy), dronabinol, testosterone and progesterone derivatives such as megestrol acetate, or in the preceding 1 week prior to study enrollment Pregnancy or lactation or unwillingness to use contraceptives A score of 11 or more, in each subscale of the Hospital Anxiety and Depression scale (HADS) indicating clinical depression or anxiety. Those with HADS scores of > 11 at baseline indicating moderate or severe depression will be excluded from the study and will be referred for appropriate follow up by counselor and psychiatry evaluation Patients on chronic use of benzodiazepines are excluded
Patient description: A 46-year-old woman presents with a 9 month history of weight loss (20 lb), sweating, insomnia and diarrhea. She reports to have been eating more than normal and that her heart sometimes races for no reason. On physical examination her hands are warm and sweaty, her pulse is irregular at 110bpm and there is hyperreflexia and mild exophthalmia.

Clinical trial eligibility criteria: eligible ages (years): 2.0-999.0,  Graves' Disease Graves' disease patients
Patient description: A 46-year-old woman presents with a 9 month history of weight loss (20 lb), sweating, insomnia and diarrhea. She reports to have been eating more than normal and that her heart sometimes races for no reason. On physical examination her hands are warm and sweaty, her pulse is irregular at 110bpm and there is hyperreflexia and mild exophthalmia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Stroke Immobilization Myofacial Pain Hyperthyroid Myopathy Normals Healthy individuals Stroke a first stroke (i.e., a unilateral, ischemic hemispheric stroke) within the previous one to two months, ability to cooperate and follow simple commands, and gastrocsoleous strength in the affected lower extremity of between trace and 50% of normal Immobilization immobilized in a cast (typically 6 weeks) following sugical repair of a severe Achilles tendon tear or rupture, ankle injury or plantar fascial pain Myofascial Pain history of pain in trapezius confirmed by clincal examination. The examiner will perform snapping palpation over the MFTP. If a localized, transient contraction is observed, the response is considered to be positive and the subject will be considered eligible for entry into the study Hyperthyroid Myopathy clinical assessment in combination with a serum hormone profile of increased Free Thyroxine (FT4) and Triiodothyronine (T3) in the face of suppressed levels of Thyroid Stimulating Hormone (TSH)